Answers are grounded in this paper and cite their sources.
This editorial provides an overview of multiple articles in the issue focusing on personalized approaches to heart failure, including the impact of age, comorbidities like diabetes and atrial fibrillation, and novel therapeutic strategies.
For the podcast associated with this article, please visit https://academic.oup.com/eurheartj/pages/Podcasts. Patients with heart failure may present in stable condition or acutely decompensated, or even in cardiogenic shock.1 The latter is most commonly caused by an acute coronary syndrome and remains a therapeutic challenge.2–5 The recent surprising results of a randomized trial investigating complete revascularization vs. culprit artery percutaneous coronary intervention only in such patients6 are discussed in a Viewpoint ‘Integrating the results of the CULPRIT-SHOCK trial in the 2017 ESC STEMI Guidelines: viewpoint of the Task Force’ by the principal author of the ESC Guidelines,7 Borja Ibanez from Centro Nacional de Investigaciones Cardiovasculares Carlos III (CNIC), IIS-Fundación Jiménez Díaz University Hospital, and CIBERCV in Madrid, Spain.8 Diabetes is both a risk factor for stroke,9 coronary artery disease, and myocardial infarction,10,11 and may also directly affect myocyte function. As such, diabetes may cause both ischaemic and non-ischaemic cardiomyopathy.12,13 In their Current Opinion entitled ‘Heart failure and diabetes: metabolic alterations and therapeutic interventions: a state-of-the-art review from the Translational Research Committee of the Heart Failure Association-European Society of Cardiology’, Stephane Heymans et al. from the University Medical Center in Maastricht, The Netherlands remind us that many novel agents emerging as promising heart failure drugs failed to improve residual morbidity and mortality. Since developing and testing new agents has become increasingly costly, the concept of repurposing existing drugs for new indications has gained considerable importance.14 Conceptually, co-morbidities such as type 2 diabetes mellitus, obesity, or chronic kidney disease, all increasingly prevalent due to the obesity epidemic, are not bystanders, but drivers of heart failure, especially of heart failure with preserved ejection fraction or HFpEF, for which no effective therapy exists.5,6 Thus, antidiabetic agents have gained interest as heart failure treatment. The Translational Research Committee of the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) provides an overview of current evidence and open issues in this context. The sympathetic as well as the parasympathetic system control the cardiovascular system15 and are deranged in heart failure.16 In a EHJ Brief Communication entitled ‘Splanchnic nerve block for decompensated chronic heart failure: Splanchnic-HF’, Marat Fudim and colleagues from the Department of Medicine, Duke Clinical Research Institute in Durham, USA note that maladaptive volume redistribution is a potential cause of acute decompensation. Elevated sympathetic tone may cause decreased vascular compliance of the main storage compartment of intravascular blood volume, i.e. the splanchnic compartment, and precipitate acute heart failure. The Splanchnic-HF Trial results are presented with haemodynamic changes, functional outcomes, comprehensive mechanistic evaluation of autonomic tone, vascular stiffness and volume shifts, and structural assessment of the heart (Figure 1).17 Renin–angiotensin inhibitors are highly evidence-based therapy for heart failure and are recommended by guidelines.1 However, in most trials, very elderly patients have not been included to a significant extent.18 In a FAST TRACK entitled ‘Association between renin–angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study’, Gianluigi Savarese from Karolinska University Hospital in Stockholm, Sweden and colleagues assessed the association between renin–angiotensin inhibitor use and mortality and morbidity in heart failure with reduced ejection fraction or HFrEF in those aged >80 years and with an ejection fraction <40%.19 Of 6710 patients, 80% received renin–angiotensin inhibitors. Using propensity score matching, renin–angiotensin inhibitors were associated with a hazard ratio of 0.78 for all-cause mortality and 0.86 for all-cause mortality and heart failure hospitalization. In aged HFrEF patients, renin–angiotensin inhibitors were underused compared with younger patients, despite a similar association with reduced morbidity and mortality and no apparent association with syncope-related hospitalizations. These clinically important results are further discussed in a thought-provoking Editorial by Marc A. Pfeffer from Brigham and Women’s Hospital, Harvard Medical School, Boston, USA,20 taking into account that registries are less reliable than randomized trials for the assessement of treatment effects.21 In another article ‘Novel endotypes in heart failure: effects on guideline-directed medical therapy’ by Peter van der Meer from the University Medical Center Groningen in The Netherlands and colleagues sought to determine subtypes of heart failure in 1802 patients using a wide range of 92 biomarkers to identify mutually exclusive subgroups (endotypes).22 Six endotypes were identified: patients with endotype 1 were youngest, less symptomatic, had the lowest N-terminal pro brain natriuretic peptide (NT-proBNP) levels, and lowest risk for all-cause mortality or hospitalization for heart failure. Patients with endotype 4 had more severe symptoms and signs of heart failure, higher NT-proBNP levels, and were at highest risk for all-cause mortality or heart failure hospitalization. Patients with endotypes 2, 3, and 5 were better up-titrated to target doses of beta-blockers. In contrast to other endotypes, patients with endotype 5 derived no potential survival benefit from up-titration of renin–angiotensin inhibitors and beta-blockers. Patients with endotype 2 even experienced possible harm from up-titration of beta-blockers, in contrast to those with endotypes 4 and 6 that experienced benefit. Thus, using unsupervised cluster analysis based on biomarkers, six distinct endotypes can be identified, with remarkable differences in characteristics, clinical outcome, and response to up-titration of guideline-directed medical therapy—a first step to personalized medicine in heart failure. Splanchnic nerve block in heart failure. (A) Study flow diagram; (B) Effects of the splanchnic nerve block on invasive haemodynamics. *P < 0.05 for a pairwise comparison with the baseline value. (C) Biomarker profile before and after splanchnic nerve block. (D) Effect of the splanchnic nerve block on shortness of breath using the Visual Analog Scale and Likert Scale, *P < 0.05 for a pairwise comparison with the baseline value (from Fudim M, Ganesh A, Green C, Jones WS, Blazing MA, DeVore AD, Felker GM, Kiefer TL, Kong DF, Boortz-Marx RL, Hernandez AF, Patel MR. Splanchnic nerve block for decompensated chronic heart failure: splanchnic-HF. See pages 4255–4256). A forest plot reporting hazard ratios for renin–angiotensin system inhibitors in pre-specified subgroups in the matched cohort aged <80 years, with P-values for interactions. EF, left ventricular ejection fraction; eGFR, estimated glomerular filtration rate (calculated by MDRD formula); HF, heart failure; NYHA, New York Heart Association (from Savarese G, Dahlström U, Vasko P, Pitt B, Lund LH. Association between renin–angiotensin system inhibitor use and mortality/morbidity in elderly patients with heart failure with reduced ejection fraction: a prospective propensity score-matched cohort study. See pages 4257–4265). In their article ‘Prognostic implications of atrial fibrillation in heart failure with reduced, mid-range, and preserved ejection fraction: a report from 14 964 patients in the ESC Heart Failure Long-Term Registry’ Offer Amir from Merkaz ha’refui al-shem Baruch Padeh Poriya in Tiberias, Israel and colleagues analysed the characteristics and 1 year prognostic of atrial fibrillation compared with sinus rhythm in HFpEF (ejection fraction ≥50%), mid-range (HFmrEF, ejection fraction 40–49%), and HFrEF (ejection fraction <40).23 In the 14 964 patients, the prevalence of atrial fibrillation was 27% in HFrEF, 29% in HFmrEF, and 39% in HFpEF, and was associated with older age, lower functional capacity, and heightened physical signs of heart failure. In each subtype, mortality and hospitalizations were higher in patients with atrial fibrillation compared with those in sinus rhythm. After adjustment, the 1-year hazard ratio of atrial fibrillation for heart failure hospitalizations was 1.036 in HFrEF, 1.430 in HFmrEF, and 1.487 in HFpEF, and for 1-year all-cause death or hospitalizations 0.957, 1.302, and 1.365, respectively (Figure 2). In patients with HFrEF, atrial fibrillation was not associated with worse outcomes in those presenting with either an acute or a chronic condition. Thus, the prevalence of atrial fibrillation increases with increasing ejection fraction. Interestingly, its association with worse 1-year cardiovascular outcomes, including heart failure hospitalizations by itself or combined with total mortality, remained significant in patients with HFpEF and HFmrEF, but not in those with HFrEF. These provocative findings are put into context in an Editorial by Peter A. Noseworthy, Mayo Clinic Minnesota in Rochester, USA.24 The issue is complemented by a Discussion Forum article entitled ‘The potential multiple effects of beta3-adrenergic receptor agonists on the heart protection for patients with heart failure with preserved ejection fraction’ by Da-xin Wang from Clinical Medical College, Yangzhou University, in Jiangsu, China and colleagues,25 referring to the original article ‘Cardiac myocyte β3-adrenergic receptors prevent myocardial fibrosis by modulating oxidant stress-dependent paracrine signalling’ by Jean-Luc Balligand from Institut de Recherche Expérimentale et Clinique (IREC), Université Catholique de Louvain (UCLouvain) in Brussels, Belgium and colleagues,26 and its corresponding reply by Balligand ‘Response to “The potential multiple effects of beta3-adrenergic receptor agonists on the heart protection for patients with heart failure with preserved ejection fraction.”’27 The editors hope that this issue of the European Heart Journal will be of interest to its readers. With thanks to Amelia Meier-Batschelet for help with compilation of this article.
No takes yet. Share an insight, caveat, or question.
Thomas F. Lüscher (2018) conducted an editorial in Heart failure.
Synapse has enriched 10 related papers. Consider them for comparative context: